2nd AnnualInvitation Only
Breast Cancer
EUFocus Meeting 2027
Two days, one room.
June 18 to 19, 2027
Stockholm, Sweden
Dates
June 18-19, 2027
Two-day program
Venue
Stockholm, Sweden
Venue TBC
Audience
26 faculty
2 co-chairs & 24 speakers · fellows TBC
Format
8 sessions · 24 talks
Talks, panels + debates
A Curated Room: The People Shaping Practice
Now in its second year, this invitation-only meeting convenes a deliberately small faculty of 26 leading breast cancer KOLs from Europe and beyond alongside hand-selected fellows and junior faculty, the clinicians defining today’s standards and the ones who will define the next decade’s, in one room for two days.
The program spans local therapy, early and metastatic HER2-positive and HR-positive disease, young patients, triple-negative breast cancer, ADC sequencing and resistance, and risk reduction and genetic predisposition. Every session closes with a moderated panel discussion, sustained, close-quarters engagement rather than a lecture hall.
Local TherapyHER2+ Early Breast CancerHR+ Early & MetastaticYoung PatientsTriple-NegativeADCs & Emerging TargetsRisk Reduction & Genetics
Meeting Co-Chairs
Listed alphabetically by surname
Javier Cortés
International Breast Cancer Center, Barcelona, Spain
Virginia Kaklamani
UT Health San Antonio, MD Anderson Cancer Center, San Antonio, TX, USA
Faculty Drawn From
Institut Curie · Gustave Roussy · The Royal Marsden · Netherlands Cancer Institute · Vall d’Hebron and other leading cancer centers in Europe and beyond
Invited attendees only, sustained access, not a crowd
1:1
KOLs to rising faculty, a hand-picked balance in every session
14
Established US Focus Meetings behind it, a proven platform, not a one-off
Talks across 8 sessions, each paired with a panel and a case
Breast Cancer EU Focus Meeting 2027
Proposed Faculty
Listed alphabetically by surname
Judith Balmaña
Vall d’Hebron Institute of Oncology, Barcelona, Spain
Carlos H. Barrios
Latin American Cooperative Oncology Group, Porto Alegre, Brazil
Rupert Bartsch
Medical University of Vienna, Austria
Giampaolo Bianchini
IRCCS Ospedale San Raffaele, Milan, Italy
François-Clément Bidard
Institut Curie, Paris, France
Javier Cortés
International Breast Cancer Center, Barcelona, Spain
Andrea De Censi
Champalimaud Foundation, Lisbon, Portugal
D. Gareth Evans
University of Manchester, UK
Alessandra Gennari
University of Piemonte Orientale, Novara, Italy
Nadia Harbeck
LMU University Hospital, Munich, Germany
Hong Hu
First People’s Hospital, Shenzhen, China
Komal Jhaveri
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Virginia Kaklamani
UT Health San Antonio, MD Anderson Cancer Center, San Antonio, TX, USA
Marleen Kok
Netherlands Cancer Institute, Amsterdam, the Netherlands
Nicla La Verde
ASST Fatebenefratelli Sacco, Milan, Italy
Matteo Lambertini
University of Genova and IRCCS Ospedale Policlinico San Martino, Italy
Kate Lathrop
UT Health San Antonio, MD Anderson Cancer Center, San Antonio, TX, USA
Antonio Llombart-Cussac
Hospital Arnau de Vilanova, Valencia, Spain
Luis Marques da Costa
Hospital de Santa Maria, University of Lisbon, Portugal
Olivia Pagani
Barbara Pistilli
Gustave Roussy, Villejuif, France
Philip Poortmans
Iridium Netwerk and University of Antwerp, Belgium
Isabel T. Rubio
Clínica Universidad de Navarra, Spain
Hope Rugo
City of Hope Comprehensive Cancer Center, Duarte, CA, USA
Nicholas Turner
The Institute of Cancer Research and The Royal Marsden, London, UK
Two Days, Eight Sessions
Proposed Faculty by Session
Presentations20 min
Panel Discussions20 min
Coffee Breaks20 min
Symposia / Expert Discussions45 min
Lunch Breaks50 min
Debates20 min
Ohio State University, Columbus, OH
Session ILocal Therapy
Moderator
Isabel T. RubioClínica Universidad de Navarra, Spain
Philip PoortmansIridium Netwerk and University of Antwerp, Belgium
Hong HuFirst People’s Hospital, Shenzhen, China
Panel Discussion
Session IIEarly Stage HER2 Positive Breast Cancer
Moderator
Giampaolo BianchiniIRCCS Ospedale San Raffaele, Milan, Italy
Luis Marques da CostaHospital de Santa Maria, University of Lisbon, Portugal
Rupert BartschMedical University of Vienna, Austria
Panel Discussion
Session IIITreatment of HR Positive MBC
Moderator
Komal JhaveriMemorial Sloan Kettering Cancer Center, New York, NY, USA
François-Clément BidardInstitut Curie, Paris, France
Nicholas TurnerThe Institute of Cancer Research and The Royal Marsden, London, UK
Panel Discussion
Session IVTreatment of Early Stage HR+ Breast Cancer
Moderator
Nadia HarbeckLMU University Hospital, Munich, Germany
Alessandra GennariUniversity of Piemonte Orientale, Novara, Italy
Antonio Llombart-CussacHospital Arnau de Vilanova, Valencia, Spain
Panel Discussion
Session VChallenges in Treating Young Breast Cancer Patients
Moderator
Olivia Pagani
Matteo LambertiniUniversity of Genova and IRCCS Ospedale Policlinico San Martino, Italy
Kate LathropUT Health San Antonio, MD Anderson Cancer Center, San Antonio, TX, USA
Panel Discussion
Session VITriple-Negative Breast Cancer
Moderator
Hope RugoCity of Hope Comprehensive Cancer Center, Duarte, CA, USA
Marleen KokNetherlands Cancer Institute, Amsterdam, the Netherlands
Speaker TBC
Panel Discussion
Session VIIADCs: Sequencing, Resistance and Emerging Targets
Moderator
Barbara PistilliGustave Roussy, Villejuif, France
Carlos H. BarriosLatin American Cooperative Oncology Group, Porto Alegre, Brazil
Nicla La VerdeASST Fatebenefratelli Sacco, Milan, Italy
Panel Discussion
Session VIIIRisk Reduction, Prevention and Genetic Predisposition
Moderator
D. Gareth EvansUniversity of Manchester, UK
Andrea De CensiChampalimaud Foundation, Lisbon, Portugal
Judith BalmañaVall d’Hebron Institute of Oncology, Barcelona, Spain
Panel Discussion
Partnership Opportunities Now Open
Bespoke engagement packages for a closed, invitation-only audience
Request the Prospectus →
